Their findings—bolstered by a specific RBM39-targeting small molecule that they demonstrate preclinical efficacy in a tumour organoid model—contribute to a growing appreciation of metabolic signalling in cancer and ground the development of new precision therapeutics against RBM39-expressing HCC. The gene discussed is RBM39; the disease is cancer.